Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation.

L F Kastrukoff1, J J Oger, W W Tourtellotte

  • 1Division of Neurology, University of British Columbia, Vancouver, Canada.

Neurology
|December 1, 1991
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genital ulcers: their diagnosis and management.

Canadian family physician Medecin de famille canadien·2011
Same author

New perspectives in multiple sclerosis.

Canadian family physician Medecin de famille canadien·2011
Same author

Granuloma inguinale: a proctologic consideration.

The New England journal of medicine·2010
Same author

Granuloma inguinale with perianal involvement; report of a case.

The New England journal of medicine·2010
Same author

Mitrofanoff continent catheterizable conduits: top down or bottom up?

Journal of pediatric urology·2008
Same author

Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss.

Journal of neurology·2008

Interferon therapy for multiple sclerosis (MS) increased immune cells (CD5+, CD4+) and central nervous system (CNS) IgG synthesis. These changes may identify patients who benefit from this treatment.

Area of Science:

  • Immunology
  • Neuroscience
  • Clinical Medicine

Background:

  • Multiple sclerosis (MS) is a chronic, progressive neurological disease.
  • Immunologic dysregulation plays a role in MS pathogenesis.
  • Lymphoblastoid interferon (IFN) is being investigated as a therapeutic agent.

Purpose of the Study:

  • To investigate immunologic functions during a placebo-controlled trial of IFN in chronic progressive (CP) MS.
  • To identify potential biomarkers for treatment response.

Main Methods:

  • Placebo-controlled trial of lymphoblastoid interferon (IFN).
  • Monitoring of CD4+, CD8+, and CD5+ cell counts in blood.
  • Measurement of central nervous system (CNS) IgG synthesis rates.
  • Assessment of serum antiviral activity.

Related Experiment Videos

  • Clinical and MRI evaluations for treatment efficacy.

    • Main Results:

    • IFN therapy increased CD5+ and CD4+ cells and decreased CD8+ cells in MS patients.
    • CNS IgG synthesis rates and serum antiviral activity increased with IFN treatment.
    • A subpopulation of 10 patients showed early increases in CNS IgG synthesis and CD5+ cells, correlating with a trend toward clinical and MRI improvement.

    Conclusions:

    • Specific immune function changes, including increased CD5+ cells and CNS IgG synthesis, may identify CP MS patients who could benefit from IFN therapy.
    • While these immune markers may predict response, they are unlikely to be the direct mediators of IFN's beneficial effects in MS.